Wall Street analysts expect AzurRx BioPharma Inc (NASDAQ:AZRX) to post earnings of ($0.21) per share for the current fiscal quarter, Zacks reports. Zero analysts have provided estimates for AzurRx BioPharma’s earnings. The highest EPS estimate is ($0.19) and the lowest is ($0.22). AzurRx BioPharma posted earnings per share of ($0.22) in the same quarter last year, which would indicate a positive year-over-year growth rate of 4.5%. The company is scheduled to announce its next quarterly earnings results on Friday, August 9th.
On average, analysts expect that AzurRx BioPharma will report full year earnings of ($0.77) per share for the current year, with EPS estimates ranging from ($0.85) to ($0.69). For the next fiscal year, analysts anticipate that the business will report earnings of ($0.72) per share, with EPS estimates ranging from ($0.79) to ($0.65). Zacks’ EPS calculations are an average based on a survey of sell-side analysts that cover AzurRx BioPharma.
AZRX has been the topic of several recent research reports. Oppenheimer set a $6.00 price objective on shares of AzurRx BioPharma and gave the company a “buy” rating in a research report on Wednesday, February 20th. Maxim Group initiated coverage on shares of AzurRx BioPharma in a research report on Thursday, February 14th. They issued a “buy” rating and a $5.00 price objective on the stock. National Securities initiated coverage on shares of AzurRx BioPharma in a research report on Tuesday. They issued a “buy” rating and a $9.00 price objective on the stock. Finally, HC Wainwright reiterated a “buy” rating and issued a $8.00 price objective on shares of AzurRx BioPharma in a research report on Thursday, February 21st. One research analyst has rated the stock with a hold rating and six have assigned a buy rating to the company’s stock. The company currently has an average rating of “Buy” and an average price target of $7.58.
NASDAQ:AZRX traded down $0.05 during mid-day trading on Wednesday, hitting $1.78. The stock had a trading volume of 51,138 shares, compared to its average volume of 96,165. The company has a market cap of $38.54 million, a PE ratio of -2.02 and a beta of 2.74. AzurRx BioPharma has a 52 week low of $1.00 and a 52 week high of $3.75.
Institutional investors have recently added to or reduced their stakes in the business. Regentatlantic Capital LLC acquired a new position in AzurRx BioPharma during the 1st quarter valued at about $48,000. Waldron Private Wealth LLC acquired a new position in AzurRx BioPharma during the 1st quarter valued at about $169,000. 683 Capital Management LLC increased its stake in AzurRx BioPharma by 73.9% during the 4th quarter. 683 Capital Management LLC now owns 695,504 shares of the company’s stock valued at $842,000 after buying an additional 295,504 shares during the period. Vanguard Group Inc increased its stake in AzurRx BioPharma by 2.1% during the 3rd quarter. Vanguard Group Inc now owns 413,439 shares of the company’s stock valued at $1,063,000 after buying an additional 8,489 shares during the period. Finally, Gilder Gagnon Howe & Co. LLC increased its stake in AzurRx BioPharma by 0.8% during the 1st quarter. Gilder Gagnon Howe & Co. LLC now owns 541,536 shares of the company’s stock valued at $1,311,000 after buying an additional 4,107 shares during the period. 13.12% of the stock is currently owned by hedge funds and other institutional investors.
About AzurRx BioPharma
AzurRx BioPharma, Inc researches and develops non-systemic biologics for the treatment of patients with gastrointestinal disorders. Its product pipeline consists of two therapeutic proteins under development, including MS1819, a yeast derived recombinant lipase, which is in Phase II clinical trial for the treatment of exocrine pancreatic insufficiency associated with chronic pancreatitis and cystic fibrosis; and AZX1101, an enzymatic combination of bacterial origin for the prevention of hospital-acquired infections and antibiotic-associated diarrhea.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for AzurRx BioPharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AzurRx BioPharma and related companies with MarketBeat.com's FREE daily email newsletter.